Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Summary

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Eligibility

Inclusion Criteria:

* Male or female patients' age from 18 years to 70 years.
* Patients who have a life expectancy of at least 3 months.
* pathologically confirmed non-small cell lung cancer.
* failed in previous standard chemotherapy and targeted therapy.
* Karnofsky performance status 0-1.
* adequate organ functions.

Exclusion Criteria:

* Pregnant and lactating women.
* Patients with T cell lymphoma, syphilis, AIDS or combination
* Patients with highly allergic or have a history of severe allergies
* Patients with severe hepatic or renal dysfunction
* Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
* Patients with severe infection not controlled or High fever
* Patients with organ transplantation or waiting for organ transplantation.
* Patients with brain metastasis
* Patients with severe coagulopathy (e.g. hemophilia)
* Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.

Conditions3

Browse More Trials